Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert


Search Title by author or title

Study to evaluate the effectiveness of an extended-depth-of-focus multifocal IOL

Poster Details

First Author: Z.Khatib INDIA

Co Author(s):    V. Shetty   S. Haldipurkar                 

Abstract Details


To assess the near, intermediate and distance visual acuity of Tecnis Symfony extended range of vision multifocal IOL.


Laxmi Eye Institute, Navi Mumbai


40 eyes of 20 patients were implanted with bilateral Symfony and/or Symfony toric IOL, with age ≥18 years, clear intraocular media and regular corneal astigmatism on topography. Patients with potential visual acuity less than 0.63 due to other ocular pathologies, history of ocular trauma or surgery, history of amblyopia, strabismus, forme frusta keratoconus or keratoconus, capsular or zonular abnormalities, prior corneal refractive surgery or patient with pupil abnormalities and retinal disorders were excluded. Uncorrected visual acuity of these patients was recorded for near (UCNVA), intermediate (UCIVA) and distance (UCDVA), at postoperative 1 month and 6 months.


Mean age of patients included was 62.8 years(SD±8.51 years). At post operative 1 month, mean UCDVA was 0.90 ± 0.16, UCIVA was 0.66 ± 0.11 and UCNVA was 0.46 ± 0.06. At 6 month follow-up, mean UCDVA was 0.97 ± 0.09, UCIVA was 0.70 ± 0.11 and UCNVA was 0.46 ± 0.05. In comparison, the best corrected visual acuity for distance at postoperative 1 month was 0.95± 0.12 (P=0.06) and at postoperative 6 month was 0.97±0.09 (P= 0.35). Similarly, the difference between near and intermediate vision between the best corrected visual acuity and UCVA was not statistically significant.


Uncorrected visual acuity outcome at near, intermediate and distance after Symfony extended depth of focus multifocal IOL implantation was comparable to the post-operative best corrected visual acuity with an insignificant p value.

Financial Disclosure:


Back to Poster listing